Cue Biopharma (NASDAQ:CUE) Azioni

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%
As recently <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 23, 2025 / <a href="https://pr.report/bqbi">Jaguar Health, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) today provided updates on the company's orphan disease intestinal failure program. Jaguar, through Jaguar family companies <a href="https://pr.report/bqbk">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/bqbl">Napo Therapeutics</a>, is currently supporting two independent proof-of-concept investigator-initiated trials (IITs), and conducting two placebo-controlled Phase 2 studies, of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions.
Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.

News

JAGX

Jaguar Health Updates On Orphan Disease Intestinal Failure Program; Completion Of Napo's Phase 2 Study Of Crofelemer In Pediatric MVID Patients Is Expected In Mid-2026 As Planned

JMP Securities analyst Patrick Walravens reiterates Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) from Market Perform to Market Perform.

Reiteration

Analyst Ratings

ADBE

JMP Securities Reiterates Market Perform on Adobeto Market Perform

Barrington Research analyst Vincent Colicchio maintains TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) with a Outperform and maintains $156 price target.

Price Target

Barrington Research Maintains Outperform on TD Synnex, Maintains $156 Price Target

<a href="https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html" title="https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html">https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html</a>

Biotech

General

Libertas Bio Licenses Gusacitinib To Sanofi

WIIM

ILMN

Standard BioTools shares are trading higher after the company announced a strategic sale of SomaLogic to Illumina.

Management

Cushman & Wakefield Announces Retirement Of Brett White As Chairman; Appoints Steve Plavin As Chairman And Independent Director

Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System
<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4453227-1&amp;h=3153541511&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a>&nbsp;("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago. These studies used an alternative second-generation approach with a non-viral lipid nanoparticle delivery system. This exploratory research represents the Company's forward-thinking work within its diabetes program to determine if the novel diabetes gene therapy can be delivered using a non-viral delivery system which could allow for repeat dosing.
 &nbsp;

GNPX

Genprex Announces That Its Research Collaborators Presented Positive Preclinical Data And Research From Studies Of Gpx-002 At The 2025 American Diabetes Association 85th Scientific Session In Chicago

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg&#8216;s apparent alignment with the MAGA movement has left many of his colleagues feeling &#8220;grieving,&#8221; and Elon Musk&#8216;s popularity was reportedly a major motivating factor behind this.
What Happened: Zuckerberg&#8217;s growing alignment with the Trump administration led to a radical transformation, leaving his employees feeling betrayed. On the other hand, some saw it as a natural transition for the Meta CEO, <a href="https://www.ft.com/content/8e7e6f5f-6f7b-4c7f-8e5e-7c9e4c1e2d8b">as</a> per the Financial Times report.
According to insiders at Meta Platforms, Zuckerberg&#8217;s shift into &#8220;MAGA Mark&#8221; was attributed to Zuckerberg&#8217;s desire to be seen as a bold and visionary innovator, a status he felt Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Musk had achieved. &#8220;He saw that Elon Musk was popular among the tech bros. There was a push to make him cool,&#8221; one source revealed.
Meta did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Some employees also recalled how Zuckerberg, in a bid to emulate Musk&#8217;s strategies, announced significant layoffs at Meta soon after Elon Musk slashed the workforce following the Twitter acquisition in 2022.
In a surprising move in January, ahead of Donald Trump&#8216;s second term inauguration,&nbsp;Zuckerberg announced that Meta's moderation&nbsp;would be relaxed and professional fact-checking would be done away with. Efforts towards diversity, equity, and inclusion would also be scaled back.
These actions have left many employees feeling betrayed, with some describing their feelings&nbsp;as "grieving", "horror" and "betrayal".&nbsp;Roger McNamee, an early investor&nbsp;turned critic, said&nbsp;Zuckerberg has become "unbelievably sensitive&nbsp;to not becoming irrelevant".
Some also believe that Trump&#8217;s warning to pursue 2020 &#8216;Election Fraudsters,&#8217; particularly Zuckerberg, also motivated the Meta CEO to warm up to Trump.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46046249/mike-pence-lauds-trumps-decisive-leadership-on-the-historic-mission-against-irans-nuclear-program-i-couldnt-be-more-proud" target="_blank" rel="noreferrer noopener">Mike Pence Lauds Trump&#8217;s &#8216;Decisive Leadership&#8217; On The &#8216;Historic Mission&#8217; Against Iran&#8217;s Nuclear Program: &#8216;I Couldn&#8217;t Be More Proud&#8217; &#8211; Benzinga</a>
Why It Matters: Zuckerberg&#8217;s evolving image and actions have been a topic of interest in recent months. Despite the controversy surrounding his public persona, Meta has been making significant moves in the tech industry and his aggressively pushed into artificial intelligence (AI). 
Recently, Sam Altman revealed how Zuckerberg&#8217;s company&nbsp;reportedly offered<a href="https://www.benzinga.com/markets/tech/25/06/45988600/mark-zuckerbergs-meta-dangled-100-million-signing-bonuses-to-openai-team-members-says-sam-altman-happy-none-of-our-best-people-took-them"> $100 million compensation</a> packages&nbsp;to lure top OpenAI talent. Furthermore,&nbsp;Meta was in talks to hire Nat Friedman, former CEO of GitHub, <a href="https://www.benzinga.com/markets/tech/25/06/46010604/mark-zuckerbergs-meta-reportedly-looking-to-hire-former-github-ceo-nat-friedman-and-investor-daniel-gross-as-part-of-aggressive-ai-expansion-strategy">to bolster</a> its AI efforts.&nbsp;
As for political alignment, Zuckerberg continues to endorse the Trump administration. In March, Trump also suggested that Meta may invest up to $60 billion in the U.S. by the end of the year amid the President&#8217;s &#8220;America-First&#8221; goal. Meanwhile, Elon Musk has currently distanced himself from politics following a feud with President Trump and vowed to focus on his business ventures.
On a year-to-date basis, Meta surged 13.44%, while Tesla slumped over 15%, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/46044108/outrage-mounts-over-trumps-appointment-of-22-year-old-to-terrorism-unit-amid-iran-crisis" target="_blank" rel="noreferrer noopener">Outrage Mounts Over Trump&#8217;s Appointment of 22-Year-Old to Terrorism Unit Amid Iran Crisis</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Mark Zuckerberg's MAGA Pivot Driven By Elon Musk Envy, Image Goals, Say 'Betrayed' Meta Insiders: Report

<a href="https://pr.report/bq8h">WidePoint Corporation</a> (NYSE American:<a href="https://pr.report/bq8i">WYY</a>), the federally certified provider of Trusted Mobility Management (TM2) solutions, announced today that it has secured a one-year, $110,000 contract to deliver Device as a Service (DaaS) management and support for a prominent Federal health research agency. This initiative is aimed at streamlining the deployment and lifecycle management of cutting-edge technologies critical to advancing innovative health solutions. This award marks the first of several material DaaS opportunities in the pipeline in collaboration with the Company's strategic Fortune 500 partner.

Widepoint Secures 1-Yr, $110K Contract To Deliver Device As A Service Management And Support For Federal Health Research Agency

<ul>
<li>Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) &nbsp;</li>
<li>RASolute 302, a Phase 3 registrational study of daraxonrasib in patients with previously treated metastatic PDAC, expected to substantially complete enrollment this year &nbsp;Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daraxonrasib, the company's RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC in patients with KRAS G12 mutations.</li>
</ul>
The Breakthrough Therapy Designation is based on encouraging data from the Phase 1 RMC-6236-001 clinical trial evaluating daraxonrasib in patients with previously treated metastatic PDAC.
"This Breakthrough Therapy Designation underscores the enormous need for new treatments for patients with pancreatic cancer and highlights the potentially important role the investigational drug, daraxonrasib, may have in helping patients living with this disease," said Mark A. Goldsmith M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "We look forward to substantially completing enrollment of the RASolute 302 study this year to enable an expected readout in 2026, and should the results support it, working closely with the FDA and other regulatory agencies around the world to bring daraxonrasib to patients as quickly as possible."
Breakthrough Therapy Designation is intended to expedite the development and review of potential new medicines designed to treat serious conditions and address significant unmet medical needs. The medicine needs to have shown encouraging preliminary clinical evidence that demonstrates substantial improvement on a clinically significant endpoint over available medicines.
More than 90% of patients living with PDAC have tumors carrying a RAS cancer driver mutation with ~85% carrying a KRAS G12 mutation. Revolution Medicines is currently enrolling patients in RASolute 302, a global Phase 3 registrational study of daraxonrasib in patients with previously treated metastatic PDAC. The study design focuses on a core population of patients with PDAC harboring RAS mutations at position 12 (RAS G12X) and an expanded population that includes patients with tumors harboring RAS mutations at position G12 (RAS G12X), G13 (RAS G13X) or Q61 (RAS Q61X), or those without any identified targetable mutation. The dual primary endpoints for the study are progression-free survival (PFS) and overall survival (OS) in the core patient population. Key secondary endpoints include PFS and OS in the expanded population of patients. Additional information about RASolute 302 (NCT06625320) is available at <a href="https://www.globenewswire.com/Tracker?data=2JUn-AmwaiVcIDwjwrMaJvMi1SGW0HAqnud64NxMQ1llQDUgxJ_afSLqj8H-OnAjPweI3fHMk8psqxeuX7qM902L1p31lnZlcTQCw2OfdhvGzkka7O96IdHcIBllREW-">clinicaltrials.gov</a>.

RVMD

Revolution Medicines Announces FDA Breakthrough Therapy Designation For Its Daraxonrasib In Previously Treated Metastatic Pancreatic Cancer With KRAS G12 Mutations

CRMD

CorMedix shares are trading higher after the company raised its Q2 net sales guidance.

6 analysts have expressed a variety of opinions on Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $11.17, a high estimate of $13.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.51%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750683663_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Park Hotels &amp; Resorts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Politzer</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Underweight</td>
<td>$10.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Park Hotels &amp; Resorts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Park Hotels &amp; Resorts compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Park Hotels &amp; Resorts's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Park Hotels &amp; Resorts's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Park Hotels &amp; Resorts analyst ratings.</a>
<h2>Get to Know Park Hotels &amp; Resorts Better</h2>
Park Hotels &amp; Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
<h3>Park Hotels &amp; Resorts: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Park Hotels &amp; Resorts's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.41%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -9.05%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Park Hotels &amp; Resorts's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Park Hotels &amp; Resorts's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.63%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Park Hotels &amp; Resorts's debt-to-equity ratio is below the industry average at 1.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Park Hotels & Resorts Stock

Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.2, along with a high estimate of $62.00 and a low estimate of $43.00. This current average represents a 4.71% decrease from the previous average price target of $54.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1750683653_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Red Rock Resorts among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Politzer</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Steve Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$44.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$45.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Eric Ross</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$55.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Stephanie Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joseph Stauff</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$52.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Red Rock Resorts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Red Rock Resorts compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Red Rock Resorts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Red Rock Resorts's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RRR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Red Rock Resorts analyst ratings.</a>
<h2>Delving into Red Rock Resorts's Background</h2>
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
<h3>Red Rock Resorts: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Red Rock Resorts displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.83%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Red Rock Resorts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Red Rock Resorts's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.37%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Red Rock Resorts's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.1% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 13.77, Red Rock Resorts faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 10 Analysts Discuss Red Rock Resorts Stock

Across the recent three months, 9 analysts have shared their insights on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $45.0, a high estimate of $56.00, and a low estimate of $38.00. This upward trend is apparent, with the current average reflecting a 8.28% increase from the previous average price target of $41.56.
<img src="https://www.benzinga.com/files/images/story/2025/1750683642_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exelixis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Exelixis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 30.62%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 5.52%. This signifies efficient management of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

What 9 Analyst Ratings Have To Say About Exelixis

During the last three months, 21 analysts shared their evaluations of DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $54.95, a high estimate of $65.00, and a low estimate of $48.00. A decline of 6.79% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750683634_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive DraftKings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Politzer</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Joseph Stauff</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$52.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Curry Baker</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Shaun Kelley</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Lance Vitanza</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Curry Baker</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>Citizens Capital Markets</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$57.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DraftKings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DraftKings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DraftKings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of DraftKings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DKNG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DraftKings analyst ratings.</a>
<h2>All You Need to Know About DraftKings</h2>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 28 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
<h3>Key Indicators: DraftKings's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: DraftKings's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 19.9%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: DraftKings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -2.4%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): DraftKings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.6%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): DraftKings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.77%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: DraftKings's debt-to-equity ratio is below the industry average at 2.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DKNG

Beyond The Numbers: 21 Analysts Discuss DraftKings Stock

Cloudflare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) short percent of float has risen 17.67% since its last report. The company recently reported that it has 8.62 million shares sold short, which is 3.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cloudflare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750683629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cloudflare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cloudflare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cloudflare's peer group average for short interest as a percentage of float is 7.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Cloudflare?

CMPS

COMPASS Pathways shares are trading lower. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial.

17 analysts have expressed a variety of opinions on Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $228.18, along with a high estimate of $253.00 and a low estimate of $192.00. Witnessing a positive shift, the current average has risen by 6.77% from the previous average price target of $213.71.
<img src="https://www.benzinga.com/files/images/story/2025/1750683626_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Darden Restaurants. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$253.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>Eric Gonzalez</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$212.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Palmer</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Andy Barish</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$210.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Eric Gonzalez</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$192.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Darden Restaurants. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Darden Restaurants compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Darden Restaurants's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Darden Restaurants's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Darden Restaurants analyst ratings.</a>
<h2>About Darden Restaurants</h2>
Darden Restaurants is the largest restaurant operator in the US full-service space, with consolidated revenue of $11.4 billion in fiscal 2024 resulting in 3%-4% full-service market share (per NRA data and our calculations). The company maintains a portfolio of 11 restaurant brands: Olive Garden, LongHorn Steakhouse, Cheddar's Scratch Kitchen, Ruth's Chris, Yard House, The Capital Grille, Seasons 52, Eddie V's, Bahama Breeze, The Capital Burger, and most recently, Chuy's. Darden generates revenue almost exclusively from company-owned restaurants, though a small network of franchised restaurants and consumer-packaged goods sales through the traditional grocery channel contribute modestly. As of the end of its fiscal 2024, the company operated 2,031 restaurants in the US.
<h3>Darden Restaurants's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Darden Restaurants displayed positive results in 3M. As of 28 February, 2025, the company achieved a solid revenue growth rate of approximately 6.16%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Darden Restaurants's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.24% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Darden Restaurants's ROE excels beyond industry benchmarks, reaching 15.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.58%, the company showcases effective utilization of assets.
Debt Management: Darden Restaurants's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.76.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Darden Restaurants's Future

Electronic Arts's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EA#NYSE">EA</a>) short percent of float has risen 18.99% since its last report. The company recently reported that it has 8.87 million shares sold short, which is 4.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Electronic Arts Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750683625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Electronic Arts has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Electronic Arts's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Electronic Arts's peer group average for short interest as a percentage of float is 3.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around Electronic Arts?

Antero Resources's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) short percent of float has fallen 3.45% since its last report. The company recently reported that it has 12.95 million shares sold short, which is 5.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Antero Resources Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750683619_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Antero Resources has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Antero Resources's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Antero Resources's peer group average for short interest as a percentage of float is 8.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Comments

Cue Biopharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO